Autoinflammatory & rare systemic diseases

Clinical and histopathological features of a population-based cohort of 95 consecutive patients with immunoglobulin G4-related disease in Stockholm, Sweden, during a five-year period

Scand J RheumatolPublished Retrospective cohort study

Authors' conclusion

IgG4-RD in Stockholm County shows a pancreatohepatobiliary-renal dominant pattern, with relatively few glandular cases compared to Asian and US cohorts. Histopathological confirmation was supportive in most biopsied patients, although many affected organs were not biopsied.

Study context

Population
Patients with an ICD-10-SE diagnosis of immunoglobulin G4-related disease (IgG4-RD) recorded 2019–2023 in Stockholm County, Sweden, identified from the Swedish National Patient Register112 registered, 95 confirmed
Participants
95 patients
Outcome
Epidemiology, organ involvement, histopathology and management of IgG4-RD
Methodological detailspopulation-based, register-based (Swedish National Patient Register), systematic medical record review
  • Population-based
  • Register-based (Swedish National Patient Register)
  • Systematic medical record review

Main finding

As reported in the abstract

Male

68%

Involvement of two or more organs

60%

Elevated serum IgG4

71%

Underwent biopsy

76%

Observational data: associations, not effects.

Further findings

Comorbidities at diagnosis

Similar to the general older population, with elevated prevalence of nasal polyposis and asthma

Treatment and prognosis

Most received systemic GC, alone or with RTX
Prognosis favourable, with high remission rates

Original publication

Clinical and histopathological features of a population-based cohort of 95 consecutive patients with immunoglobulin G4-related disease in Stockholm, Sweden, during a five-year period. Scand J Rheumatol. Published 16 June 2026. doi:10.1080/03009742.2026.2673625

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.